Trial | NCT00691964  Report issue

Title

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    347
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
Study Started
May 31
2008
Primary Completion
Mar 31
2009
Study Completion
Mar 31
2009
Last Update
Jan 21
2013
Estimate

Biological ABT-874

SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8

Biological etanercept

SQ injection 50 mg BIW

Drug placebo

SQ placebo injections for ABT-874 and etanercept

A Experimental

B Active Comparator

C Placebo Comparator

Criteria 

Inclusion Criteria:

Diagnosis of Psoriasis for 6 mo.
BSA 10%, PASI 12 or above, PGA 3 or above

Exclusion Criteria:

Previous exposure to either etanercept or ABT-874
No Results Posted